Nigil Haroon, MD, PhD

Opinion

Newer IL-17 inhibitors make their case in phase 3 nonradiographic axial spondyloarthritis trials

Author:

Nigil Haroon, MD, PhD

There appears to be very little to favor either ixekizumab or secukinumab over the other.

• Read More